Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

381.32USD
3:59pm EST
Change (% chg)

$0.54 (+0.14%)
Prev Close
$380.78
Open
$383.37
Day's High
$387.50
Day's Low
$379.09
Volume
200,686
Avg. Vol
290,050
52-wk High
$543.50
52-wk Low
$340.13

Chart for

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.52
Market Cap(Mil.): $40,910.86
Shares Outstanding(Mil.): 107.44
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Regeneron Announces FDA Acceptance Of SBLA Filing For 12-Week Dosing Of Eylea(Aflibercept) Injection For Patients With Wet AMD

* REGENERON ANNOUNCES FDA ACCEPTANCE OF SBLA FILING FOR 12-WEEK DOSING OF EYLEA® (AFLIBERCEPT) INJECTION FOR PATIENTS WITH WET AMD

7:15am EST

BRIEF-Regeneron And Decibel Therapeutics Announce Strategic Collaboration

* REGENERON AND DECIBEL THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP THERAPEUTICS FOR HEARING LOSS AND TINNITUS

Nov 29 2017

Regeneron drops eye-drug combination as Novartis chases Eylea

Regeneron Pharmaceuticals is dropping plans to develop a new eye drug combination, marking a setback for the U.S. biotech company as Swiss rival Novartis seeks to snatch sales from its existing Eylea medicine.

Nov 27 2017

Regeneron drops eye-drug combination as Novartis chases Eylea

Nov 27 Regeneron Pharmaceuticals is dropping plans to develop a new eye drug combination, marking a setback for the U.S. biotech company as Swiss rival Novartis seeks to snatch sales from its existing Eylea medicine.

Nov 27 2017

Swiss stocks - Factors to watch on Nov 13

ZURICH, Nov 13 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 9,159 points on Monday, according to premarket indications by bank Julius Baer .

Nov 13 2017

German stocks - Factors to watch on November 13

BERLIN/FRANKFURT, Nov 13 The following are some of the factors that may move German stocks on Monday:

Nov 13 2017

Novartis posts eye drug data amid play for Eylea's turf

ZURICH Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

Nov 10 2017

Novartis posts eye drug data amid play for Eylea's turf

ZURICH, Nov 10 Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

Nov 10 2017

Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales

Regeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for flagship eye treatment Eylea and its new eczema drug Dupixent, boosting its shares almost 7 percent.

Nov 08 2017

UPDATE 3-Regeneron Q3 profit easily tops Street view on Eylea, Dupixent sales

Nov 8 Regeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for flagship eye treatment Eylea and its new eczema drug Dupixent, boosting its shares almost 7 percent.

Nov 08 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.00 -0.10
Pfizer Inc. (PFE.N) $36.21 +0.47
Bayer AG (BAYGn.DE) €105.15 +0.45
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.58 +0.40
Merck & Co., Inc. (MRK.N) $56.34 +0.77
Amgen, Inc. (AMGN.OQ) $176.83 +1.42
Roche Holding Ltd. (ROG.S) CHF240.60 +0.10
Roche Holding Ltd. (RO.S) CHF243.20 +0.70
Eli Lilly and Co (LLY.N) $86.67 +0.22

Earnings vs. Estimates